TY - JOUR

T1 - Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics

T2 - a systematic review and meta-analysis

AU - Šuler Baglama, Špela

AU - Peteln, Irena

AU - Jemec, Gregor B.E.

N1 - Publisher Copyright: © 2022 Taylor & Francis Group, LLC.

PY - 2022

Y1 - 2022

N2 - Background: Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective: This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK. Methods: This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase. Results: 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents–21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p =.252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy. Conclusion: Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.

AB - Background: Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective: This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK. Methods: This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase. Results: 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents–21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p =.252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy. Conclusion: Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.

KW - actinic keratoses

KW - Chemotherapy

KW - inflammation

KW - treatment

U2 - 10.1080/09546634.2022.2131298

DO - 10.1080/09546634.2022.2131298

M3 - Review

C2 - 36190770

AN - SCOPUS:85139799975

VL - 33

SP - 3136

EP - 3142

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 8

ER -